Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Wistar Institute Of Anatomy & Biology has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This workload is handled by 2 distinct examiners across 2 distinct art units. JUEDES, AMY E is the busiest examiner for the portfolio, currently responsible for 1 pending office action.
Because the 2 pending office actions are spread across different examiners, the company's prosecution risk is diversified. This arrangement requires the company to navigate the procedural nuances of different art units simultaneously. Practitioners should focus on the individual tendencies of each examiner to ensure consistent progress across the active applications. The use of 2 distinct art units indicates that the institute's biotechnology research is being evaluated under different sets of examination guidelines, which may require distinct arguments for each case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013542 | CD4+HELPER EPITOPES AND USES TO ENHANCE ANTIGEN-SPECIFIC IMMUNE RESPONSES | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18013542 | CD4+HELPER EPITOPES AND USES TO ENHANCE ANTIGEN-SPECIFIC IMMUNE RESPONSES | JUEDES, AMY E | 1644 | §102§103§112DP | Final Rejection | — | Pending | Dec 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial